secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001628280-22-020811
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q2 2022 revenue up to $28.2M; net loss narrows to $0.25/share
---------------------------------------------------------------------

- Q2 net product revenue $28.2M vs $6.6M YoY; six month revenue $49.8M.
- Net loss $35.5M ($0.25/share) vs $47.0M ($0.37) in Q2 2021.
- LUPKYNIS patients on treatment ~1,274 at June 30, up 19% from Q1 2022.
- 2022 net revenue guidance reaffirmed at $115-$135M.
- Positive CHMP opinion in Europe; EC decision expected by end of Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022020811/0001628280-22-020811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022020811/auph-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-020811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer